7,300
Participants
Start Date
January 12, 2023
Primary Completion Date
January 1, 2029
Study Completion Date
March 1, 2029
CAC-based treatment strategy
The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
Standard treatment
Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
RECRUITING
Odense University Hospital, Odense
Odense University Hospital
OTHER
Per Løgstrup Poulsen
OTHER